Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04006132
Other study ID # C71
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 4, 2019
Est. completion date January 10, 2020

Study information

Verified date January 2020
Source Oticon Medical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the benefit of bilateral implantation with bone-anchored hearing systems (BAHS), in terms of sound localization abilities, as well as auditory working memory. The hypothesis is that the use of two BAHS (bilateral condition) will not only improve localization abilities, but it will also increase the ability to retain words in working memory, compared to performance with only one BAHS (unilateral condition).


Description:

The patients included in this study are adult patients with a bilateral conductive or mixed hearing loss, that are already bilaterally implanted with two percutaneous bone-anchored devices (BAHS). The study consists of two visits. At visit 1, the patients are fitted unilaterally and bilaterally with the investigational device (Ponto 3 SuperPower). After fitting, the patients perform a test of spatial resolution (minimum audible angle, visit 1) and an auditory working memory test (visit 2). These two outcome measures are conducted in the laboratory using the Ponto 3 SuperPower unilaterally and bilaterally. Additionally, the patients fill in a questionnaire (SSQ12) to report perceived performance in their everyday life with their own devices. This is a post market study and all products used are CE marked and used in clinical practice worldwide.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 10, 2020
Est. primary completion date January 7, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Adult BAHS users, minimum 18 years and maximum 75 years.

- Native English speakers.

- Patients that are already bilaterally implanted.

- Patients with a bilateral conductive or mixed conductive-sensorineural hearing loss.

- Experience with bilateral Ponto of at least 6 months.

- Patients that are using both their sound processors daily.

- PTA BC (at 0.5, 1, 2, 3 kHz) on both sides lower or equal to 65 dB HL.

- If the masked BC is available on the patient's journal, the average difference in masked BC (at 0.5, 1, 2, 4 kHz) between L and R ear should be lower than 15 dB.

- If the masked BC is not available on the patient's journal, the average difference in unmasked BC (at 0.5, 1, 2, 4 kHz) between L and R ear should be lower than 15 dB.

Exclusion Criteria:

- Not deemed suited by the principal investigator.

- If the physician assesses that the patient is not fit for trial participation at any stage.

- Audiogram at 1st visit shows too large masked BC thresholds (PTA BC - at 0.5, 1, 2, 3 kHz - on either side larger than 65 dB HL).

- Audiogram at 1st visit shows asymmetric masked BC thresholds (average difference in masked BC - at 0.5, 1, 2, 4 kHz - between L and R ear larger or equal to 15 dB).

Study Design


Intervention

Device:
Fitting of Ponto 3 SuperPower
Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.

Locations

Country Name City State
United Kingdom Audiology Department, Nuffield House, University Hospitals Birmingham Birmingham West Midlands

Sponsors (1)

Lead Sponsor Collaborator
Oticon Medical

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Minimum Audible Angle test Minimum angle at which noise bursts are accurately localized (Right/Left) in the unilateral and bilateral conditions 4 months
Secondary SWIR test Percentage of recalled words in the unilateral and bilateral conditions 4 months
Secondary SSQ12 Subjective performance as measured by Speech, Spatial and Qualities of Hearing questionnaire (SSQ); 12 items with a scale from 0-10 where 0 represents "Not at all" and 10 represents "Perfect" 4 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04750642 - Cochlear Implant With Dexamethasone Eluting Electrode Array N/A
Recruiting NCT05955469 - Comparison in New Cochlear Implanted Subjects of a Tonotopy-based Bimodal Fitting and a Conventional Fitting N/A
Terminated NCT04242940 - Assessing Listening Effort at Different Signal-to-noise Ratios in Bone-anchored Users N/A
Active, not recruiting NCT05540535 - Dual-Task Cost in Bilateral Hearing Loss
Active, not recruiting NCT00763243 - Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants N/A